SCM
IFRX icon

Scopia Capital Management’s InflaRx IFRX Stock Holding History

Scopia Capital Management’s Portfolio IFRX Stock Details IFRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-205,080
Closed -$7.04M – 31
2018
Q3 		$7.04M Buy
+205,080
New +$6.61M 0.14% 36

Other funds holding IFRX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Scopia Capital Management's IFRX Position: Q4 2018 in Review

Scopia Capital Management sold out of InflaRx (IFRX) in Q4 2018, closing a stake of 205,080 shares — an estimated $7.04M sold.

Scopia Capital Management first reported a position in IFRX in Q3 2018 and held it in 1 quarter. The position peaked at $7.04M in Q3 2018. 34 funds tracked by Wall St. Rank hold IFRX as of Q4 2018.

  • Scopia Capital Management reported no remaining InflaRx position as of Q4 2018 after selling out during the quarter.
  • Scopia Capital Management sold 205,080 InflaRx shares in Q4 2018, an estimated $7.04M.
  • Scopia Capital Management first reported a position in InflaRx in Q3 2018 and held it in 1 quarter.
  • Scopia Capital Management's InflaRx position peaked at $7.04M in Q3 2018.
  • 34 funds tracked by Wall St. Rank held InflaRx as of Q4 2018.

Based on Scopia Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.